Introduction
Prostate cancer develops in the prostate gland—a walnut-sized organ below the bladder in men that produces seminal fluid. It is one of the most common cancers in men, often growing slowly in early stages.
Many tumors remain localized for years; some are aggressive and spread to bone and lymph nodes. Screening with PSA blood test and digital rectal exam is individualized based on age and risk.
Treatment options include active surveillance, surgery, radiation, hormone therapy, and newer agents for advanced disease. Choice depends on stage, grade (Gleason/Grade Group), age, and overall health.
This page explains risk factors, symptoms, diagnosis, and treatment pathways.
Overview
Adenocarcinoma of prostate arises from glandular epithelium. Multiparametric MRI and targeted biopsy improve detection of clinically significant cancers while reducing overdiagnosis of indolent disease.
Prognosis for localized disease is excellent; metastatic disease is treatable but generally not curable—focus shifts to control and quality of life.
- Common male cancer; often slow-growing
- PSA screening controversial—shared decision-making
- Localized: surgery, radiation, or active surveillance
- Advanced: androgen deprivation plus systemic therapy
- Bone is common metastatic site
- Many men die with rather than of prostate cancer
What happens in the body
Genetic and hormonal factors (androgens) promote prostate epithelial transformation. Accumulated mutations lead to uncontrolled growth within prostate and potential invasion through capsule and vasculature.
Androgen receptor signaling drives most prostate cancers even after initial treatment, until neuroendocrine transformation in late disease.
- Androgen-dependent growth in typical prostate cancer
- Local spread to seminal vesicles and bladder neck
- Lymphatic and hematogenous metastasis to bone
- PSA reflects prostate tissue activity—not perfect cancer marker
- Grade Group predicts aggressiveness
Signs and symptoms
Early prostate cancer often has no symptoms; later signs include:
- Often asymptomatic when localized
- Urinary frequency, weak stream, nocturia ( overlap with BPH)
- Blood in urine or semen
- Erectile dysfunction
- Bone pain in spine, hips if metastatic
- Weight loss and fatigue in advanced disease
- Urinary retention rare from cancer obstruction
- Leg swelling if nodal obstruction (advanced)
Causes and risk factors
Risk increases with several factors:
- Age—most common after 50
- African ancestry higher risk and mortality
- Family history of prostate or related cancers
- BRCA2 and other inherited mutations
- Obesity linked to aggressive disease
- Not proven directly caused by vasectomy or sexual activity
- Diet high in processed meat debated as minor factor
Diagnosis and evaluation
Diagnosis requires tissue confirmation after suspicion raised:
- PSA blood test trends and age-specific interpretation
- Digital rectal exam for nodules
- Multiparametric prostate MRI before biopsy
- Transrectal ultrasound-guided biopsy with Gleason grading
- Grade Group and staging (TNM) for treatment planning
- Bone scan or PSMA PET for high-risk or symptomatic metastatic suspicion
- Germline testing in metastatic or strong family history
Treatment and management
Risk-stratified management from watchful waiting to multimodal therapy:
- Active surveillance for very low/low-risk localized disease
- Radical prostatectomy (open, robotic, or laparoscopic)
- External beam radiation or brachytherapy
- Androgen deprivation therapy (ADT) for advanced or high-risk combined modality
- Abiraterone, enzalutamide, chemotherapy, PARP inhibitors in metastatic castration-resistant disease
- Bone-targeted agents (bisphosphonates, denosumab, radium-223)
- Pelvic floor rehab for urinary continence after treatment
- Palliative care integration for advanced disease
Prevention, self-care, and lifestyle
Not every condition is fully preventable, but the steps below may lower risk or recurrence:
- No proven prevention; healthy weight and exercise may lower aggressive risk
- Informed PSA screening decision with clinician starting ~55 (earlier if high risk)
- Discuss family history for genetic counseling
- Smoking cessation supports overall cancer outcomes
Possible complications
Delay, missed care, or unsafe self-medication can raise the chance of complications in some cases:
- Urinary incontinence and erectile dysfunction after treatment
- Metastatic bone pain and fractures
- ADT side effects: hot flashes, bone loss, metabolic changes
- Treatment anxiety and overtreatment of indolent cancers
- Progression despite therapy in advanced cases
When to see a doctor or seek emergency care
Seek prompt medical advice or emergency care if any of the following apply—it is safer not to wait and see:
- Discuss PSA screening based on age and risk
- Persistent bone pain or unexplained weight loss
- Blood in urine or semen
- Urinary obstruction not explained by infection
- Abnormal DRE or rising PSA per urologist advice
Living with the condition
Many men on active surveillance live years without treatment side effects, with regular monitoring. Treatment decisions should weigh longevity goals against urinary and sexual function priorities.
Support groups and survivorship care address long-term ADT effects and emotional adjustment after diagnosis.
Frequently asked questions
Does a high PSA always mean cancer?
No. BPH, infection, and recent ejaculation can raise PSA. Biopsy confirms cancer when suspicion persists.
Can prostate cancer be cured?
Localized disease is often curable with surgery or radiation. Metastatic disease is usually managed long-term rather than cured.
Should every man get screened?
Guidelines differ. Shared decision-making considers age, health, and risk—benefits and harms of screening are discussed individually.
Important caution
This article is general health education in English. It is not personal medical advice.
Prostate symptoms and screening decisions should involve a qualified urologist or primary clinician.
Bone pain with cancer history requires prompt oncologic evaluation.